GeneDx class action lawsuit
Analysis based on 6 articles · First reported Jul 22, 2026 · Last updated Jul 24, 2026
GeneDx Holdings Corporation's stock price dropped 49.2% following the Q1 results announcement. The class action lawsuit may further pressure the stock and increase legal costs.
Pomerantz LLP filed a class action lawsuit against GeneDx Holdings Corporation Holdings Corp. (Nasdaq:WGS) alleging securities fraud. The suit concerns GeneDx Holdings Corporation's acquisition of Fabric Genomics and subsequent Q1 2026 results that revealed a drop in adjusted gross margin from 74% to 69%, reduced projected earnings, and a $31.3 million impairment loss. GeneDx Holdings Corporation's stock fell 49.2% on May 5, 2026. Investors have until August 3, 2026 to seek lead plaintiff status.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard